Acadia Pharmaceuticals (ACAD) Interest & Investment Income (2010 - 2026)

Acadia Pharmaceuticals' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 1.95% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $31.9 million (up 14.44% YoY), while the FY2025 annual figure was $31.7 million, up 24.61% from the prior year.
• Interest & Investment Income was $8.1 million for Q1 2026 at Acadia Pharmaceuticals, down from $8.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $8.3 million in Q4 2025 to a low of $105000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $5.2 million across 5 years, with a median of $5.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income slumped 47.5% in 2022, then surged 3519.05% in 2023.
• A 5-year view of Interest & Investment Income shows it stood at $3.6 million in 2022, then jumped by 31.1% to $4.8 million in 2023, then jumped by 47.24% to $7.0 million in 2024, then advanced by 18.91% to $8.3 million in 2025, then dropped by 3.32% to $8.1 million in 2026.
• The last three Interest & Investment Income figures came in at $8.1 million (Q1 2026), $8.3 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.